Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY24 results · Apr–Jun 2023
Marksans Pharma reported revenue from operations of ₹500.03 crore (up 15.3% from Q1 FY23) and net profit of ₹70.44 crore (up 17.0% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 500.03 | 433.77 | +15.3% | 485.98 | +2.9% |
| Other income | 10.10 | 16.50 | −38.8% | 11.01 | −8.3% |
| Total income | 510.13 | 450.27 | +13.3% | 496.99 | +2.6% |
| Profit before tax | 96.83 | 76.44 | +26.7% | 104.17 | −7.1% |
| Net profit for the period | 70.44 | 60.18 | +17.0% | 82.71 | −14.8% |
| Attributable to shareholders of the company | 68.66 | 59.72 | +15.0% | — | — |
| EPS, basic (₹) | 1.52 | 1.46 | not comparable | 1.97 | −22.8% |
| Net margin (%) | 14.1 | 13.9 | 17.0 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 182.04 | 159.15 | +14.4% | 153.04 | +18.9% |
| Other income | 32.62 | 19.43 | +67.9% | 4.30 | +658.1% |
| Total income | 214.66 | 178.58 | +20.2% | 157.35 | +36.4% |
| Profit before tax | 54.40 | 25.70 | +111.6% | 22.84 | +138.1% |
| Net profit for the period | 44.19 | 19.21 | +130.1% | 17.81 | +148.1% |
| EPS, basic (₹) | 0.98 | 0.47 | not comparable | 0.43 | +127.9% |
| Net margin (%) | 24.3 | 12.1 | 11.6 |
Consolidated
- Filed with BSE
- 11 Aug 2023, 18:59 IST
- Board meeting
- 11 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2023, 18:59 IST
- Board meeting
- 11 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE